Written by Catharine Paddock, PhDResearchers in the UK found that alemtuzumab, a drug initially developed to treat leukemia, stopped the advance of multiple sclerosis (MS) in patients with early stage active relapsing-remitting multiple sclerosis (RRMS)...[read article]
No comments:
Post a Comment